Large M&A Deals

Transcript

Andy and JT welcome you to another episode of The Deal Board Podcast. This week, Andy speaks with Andrew Bab of Debevoise & Plimpton about the high-stakes world of healthcare mergers and acquisitions. From billion-dollar deal structures and the teams required to execute them, to the common reasons major transactions fall apart, Andy and Andrew unpack the complexity behind large-scale deals. They also explore how private equity’s “dry powder” — the trillions of dollars firms keep in reserve to deploy into future deals — and the rise of AI-driven healthcare solutions are shaping the future of the industry. Tune in for an insider’s view of what it takes to get big deals across the finish line and where opportunities are emerging in healthcare M&A!

Key Takeaways

Key Takeaways From This Episode:

[00:30] An overview of today’s topic: Large M&A deals.

[03:00] Introducing Andrew Bab and his path from investment banking to law and healthcare M&A.

[07:04] The current state of healthcare and M&A amid market uncertainty, regulation, and healthcare antitrust hurdles.

[09:55] Impact of increased interest rates and private equity’s $2–3 trillion in “dry powder”.

[12:17] Why large deals require extensive legal, banking, and accounting teams.

[16:19] Deal timelines: negotiation, signing, and regulatory approvals.

[17:40] Common reasons deals collapse, including valuation disputes and antitrust concerns.

[20:26] The impact of AI-driven solutions on healthcare M&A deals.

[22:35] Challenges in healthcare, from staffing shortages to drug pricing pressures.

[26:14] Deal of the Week: Alexander Woo (Orange County) sold a long-standing hair salon to a buyer who wanted an affordable way to enter the business before the seller’s move abroad.

[29:20] Listing of the Week: Rally De Leon (Raleigh) is selling a premier cabinet refacing franchise in a booming market with strong sales and growth potential.

Show Notes

Quotes:

“One of the headwinds for healthcare now is growing regulation. One of the areas that Trump is not relaxing [is] in antitrust [and] healthcare.” — Andrew Bab [0:08:01]

“One reason deals die is a lack of agreement on the valuation of a certain aspect of the company.” — Andrew Bab [0:17:45]

[Text Wrapping Break]“I think that they will be investing more in AI driven healthcare technologies. No question. Both in drug discovery [and] in the pharma space.” — Andrew Bab [0:20:33]

Longer Quotes: “You can get to a point where the antitrust authorities are signaling you that [they’re going to give] you a second request. A second request is a multi million dollar process, because you’ve got to basically give every piece of paper that exists to the antitrust authorities. — So many people don’t want to go through that, and they build into their agreements an ability to get out of the deal in that case.” — Andrew Bab [0:19:35]

Mentioned in This Episode

• The Deal Board Podcast
• The Deal Board Podcast YouTube Channel
• United Franchise Group
• https://www.tworld.com/
• https://www.linkedin.com/company/transworld-business-advisors
• https://www.facebook.com/transworldbusinessadvisors/